Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques

Luca Micci, Emory University
Emily S. Ryan, Emory University
Rémi Fromentin, Université de Montréal
Steven Bosinger, Emory University
Justin L. Harper, Emory University
Tianyu He, University of Pittsburgh
Sara Paganini, Emory University
Kirk Easley, Emory University
Ann Chahroudi, Emory University
Clarisse Benne, Case Western Reserve University

Only first 10 authors above; see publication for full author list.

Journal Title: Journal of Clinical Investigation
Volume: Volume 125, Number 12
Publisher: American Society for Clinical Investigation | 2015-12-01, Pages 4497-4513
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1172/JCI81400
Permanent URL: https://pid.emory.edu/ark:/25593/rmvhn

Final published version: http://dx.doi.org/10.1172/JCI81400

Copyright information:
© 2015, American Society for Clinical Investigation

Accessed December 11, 2018 10:02 AM EST
Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques

Luca Micci,1 Emily S. Ryan,1 Rémi Fromentin,2 Steven E. Bosinger,1,9 Justin L. Harper,1 Tianyu He,4 Sara Paganini,1 Kirk A. Easley,5 Ann Chahroudi,1,10 Clarisse Benne,7 Sanjeev Gumber,6,9 Colleen S. McGary,1 Kenneth A. Rogers,1 Claire Deleage,10 Carissa Lucero,10 Siddappa N. Byrareddy,9 Cristian Apetrei,4 Jacob D. Estes,10 Jeffrey D. Lifson,10 Michael Piatak Jr.,10 Nicolas Chomont,2 Francois Villinger,1,3 Guido Silvestri,1,3 Jason M. Brenchley,11 and Mirko Paiardini1,9

1 Division of Microbiology and Immunology, Yerkes National Primate Research Center (YNPRC), Emory University School of Medicine, Atlanta, Georgia, USA. 2 Department of Microbiology, Infectiology, and Immunology, Université de Montréal, Faculty of Medicine, and Centre de Recherche du CHUM, Montreal, Quebec, Canada. 3 Yerkes Nonhuman Primate Genomics Core, Emory University, Atlanta, Georgia, USA. 4 Center for Vaccine Research, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 5 Department of Biostatistics and Bioinformatics, Rollins School of Public Health, and 6 Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA. 7 Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA. 8 Division of Pathology, Yerkes National Primate Research Center, Atlanta, Georgia, USA. 9 Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. 10 AIDS Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, Maryland, USA. 11 Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.

Despite successful control of viremia, many HIV-infected individuals given antiretroviral therapy (ART) exhibit residual inflammation, which is associated with non–AIDS-related morbidity and mortality and may contribute to virus persistence during ART. Here, we investigated the effects of IL-21 administration on both inflammation and virus persistence in ART-treated, SIV-infected rhesus macaques (RMs). Compared with SIV-infected animals only given ART, SIV-infected RMs given both ART and IL-21 showed improved restoration of intestinal Th17 and Th22 cells and a more effective reduction of immune activation in blood and intestinal mucosa, with the latter maintained through 8 months after ART interruption. Additionally, IL-21, in combination with ART, was associated with reduced levels of SIV RNA in plasma and decreased CD4+ T cell levels harboring replication-competent virus during ART. At the latest experimental time points, which were up to 8 months after ART interruption, plasma viremia and cell-associated SIV DNA levels remained substantially lower than those before ART initiation in IL-21–treated animals but not in controls. Together, these data suggest that IL-21 supplementation of ART reduces residual inflammation and virus persistence in a relevant model of lentiviral disease and warrants further investigation as a potential intervention for HIV infection.

Introduction

While combination antiretroviral therapy (ART) has dramatically improved the prognosis of HIV-infected individuals, a scalable treatment that can cure this infection is still not available. Residual disease in ART-treated HIV-infected individuals consists mainly of (a) persistent immune abnormalities, including inflammation and immune activation, limited CD4+ T cell reconstitution, and mucosal immune dysfunction (1), and (b) persistent reservoirs of latently infected cells that are not affected by ART and are responsible for the rapid rebound of virus replication upon ART discontinuation (2). Elevated levels of inflammation and immune activation that can persist even in ART-treated HIV-infected individuals with effective viral suppression have emerged as key correlates of morbidity and mortality from non-AIDS complications such as cardiovascular disease, neurocognitive dysfunction, and kidney and bone abnormalities, among others (1, 3). Furthermore, residual inflammation may contribute to HIV persistence during ART by several mechanisms, such as favoring de novo infection of activated “target” CD4+ T cells that replenish the reservoir and upregulating the expression of immune checkpoint blockers that may limit the function of HIV-specific immune responses (1, 3, 4). Therefore, a vicious cycle in which inflammation, poor antiviral responses, and HIV persistence are intimately connected may occur in ART-treated HIV-infected individuals.

IL-21 is a pleiotropic cytokine that promotes the maintenance and functionality of Th17 cells (5–7), a subset of CD4+ T cells critical for mucosal immunity (8–14). Previously, we have shown that loss of intestinal IL-21–producing cells in the gut of SIV-infected rhesus macaques (RMs) is associated with the severity of Th17 cell depletion (15). Thus, reduced IL-21 availability may contribute to the loss of antimicrobial mucosal immunity and the induction and/or maintenance of mucosal immune dysfunction and associated pathological chronic immune activation during HIV infection. Consistent with this model, we showed that administration of a rhesus IL-21–
IgFc fusion protein during acute SIV infection of RMs results in the preservation of intestinal Th17 cells, improved mucosal immune function, and reduced microbial translocation (16).

In the current study, we investigated the effects of exogenous IL-21 administration on residual immune activation and virus persistence in ART-treated, chronically SIV-infected RMs. Our findings, generated in a relevant primate model of lentiviral infection, indicate that IL-21 administration may have a significant beneficial effect on reducing residual inflammation and virus persistence during ART.

Results

Experimental design and antiretroviral therapy. Sixteen adult, Indian-origin RMs were infected i.v. with 300 50% tissue culture infective dose (TCID50) SIVmac239. Beginning on day 60 after infection (day 60 p.i.), all animals were treated with a 5-drug antiretroviral regimen — PMPA (tenofovir), FTC (emtricitabine), raltegravir, and ritonavir-boosted darunavir — for 7 months (as indicated by the gray shading in Figure 1). Eight RMs (IL-21-treated) also received rhesus IL-21-IgFc fusion protein at 100 μg/kg (s.c.), which is a dosage comparable to that used in human clinical trials (17). The IL-21-treated RMs received 2 cycles of 6 weekly doses — 1 at the time of ART initiation and 1 later on while on ART — plus 4 additional weekly doses at the time of ART interruption (orange arrows in Figure 1). The weekly dose regimen was selected on the basis of our previous study of IL-21 administration during acute SIV infection of RMs (16), as well as of our experience with in vivo administration of other cytokines in nonhuman primates (NHPs), in which weekly doses were better tolerated and showed a better response profile than did more frequent dosages (18–20). The remaining 8 RMs were treated only with ART and served as controls. Peripheral blood (PB), colorectal mucosa (RB), and lymph node (LN) biopsies were collected longitudinally and at necropsy (Figure 1A). Plasma viral load (log10) before ART initiation was comparable between the 2 groups (i.e., ART alone versus ART plus IL-21) at all experimental time points. Thus, while ART was effective at suppressing virus replication and improved CD4+ T cell restoration, supplementation with IL-21 did not improve the reconstitution of CD4+ T cells in either blood or tissues.

Effects of IL-21 supplementation on blood and LN CD8+ T cell and B cell levels. We next assessed the effects of IL-21 on total CD8+ T cell and B cell levels as well as on their main differentiation subsets in PB and LN. The levels of blood (percentages and counts), LN (percentages), and RB (percentages) CD8+ T cells (Supplemental Figure 2) and their subsets (data not shown) were overall very similar in IL-21-treated and control RMs, with no significant differences between the 2 groups at any single experimental time point. Previous studies showed that IL-21 stimulates the production of cytotoxic molecules in CD8+ T cells in humans in vitro (21) and in acutely SIV-infected RMs in vivo (16). Hence, we sought to determine by flow cytometry the longitudinal expression of intracellular perforin, granzyme B (GrB), and T-bet in blood and LN CD8+ T cells. No significant differences were noted in the fraction of CD8+ T cells expressing any of these markers (Supplemental Figure 3), or a combination of them (data not shown), between IL-21-treated and control RMs. Similar to CD8+ T cells, the percentages of blood and LN B cells (CD20−), as well as their naive (CD21+CD27−), resting memory (CD21−CD27+), activated memory (CD21−CD27+), and tissue memory (CD21−CD27−) subsets (Supplemental Figure 4), were not affected by IL-21 treatment when assessed by flow cytometry (Supplemental Figure 4). Interestingly, IHC analyses of LN biopsies showed that IL-21–treated animals had significantly higher levels of B cells in the medulla when compared with controls (Supplemental Figure 5), thus suggesting that increased availability of IL-21 in the LN (as determined by IHC staining, data not shown) can impact the anatomic distribution of B cells during SIV infection.

IL-21 increases intestinal Th17 and Th22 cell levels in ART-treated, SIV-infected RMs. To assess the effects of IL-21 treatment on mucosal immunity, we next measured the levels of intestinal Th17 and Th22 cells, identified as CD4+ T cells producing IL-17 and IL-22, respectively, after brief in vitro stimulation with PMA and ionomycin. Representative staining of IL-17 (Figure 2A) and IL-22 (Figure 2B) within the intestinal CD4+ T cells is shown in 1 IL-21-treated and 1 control RM before infection (day 20), before ART (day 58 p.i.), and at 3 time points when on ART. The reconstitution of intestinal Th17 (Figure 2C) and Th22 (Figure 2D) cells was very limited in the RMs treated with ART alone, while IL-21 supplementation was associated with a faster and more pronounced reconstitution of both cell types. Indeed, IL-21-treated RMs showed significantly higher frequencies of Th17 and Th22 cells compared with frequencies in control animals at day 85 p.i. (day 25 on ART; Th17: P = 0.0003, Th22: P = 0.0096), day 135 p.i. (Th17: P = 0.0029; Th22: P = 0.0148), and day 203 p.i. (Th17: P = 0.0052) (Figure 2, C and D). Remarkably, in IL-21–treated animals, the frequencies of Th17 cells on days 85 and 135 p.i. were
Figure 1. Longitudinal variations in viremia and CD4+ T cell levels in IL-21–treated and control SIV-infected RMs. (A). Schematic of the study design. Sixteen RMs were infected i.v. with 300 TCID₅₀ SIVmac₂₃⁹ (day 0), and starting on day 60 p.i., treated with combination ART (PMPA, FTC, raltegravir, and ritonavir-boosted darunavir) for 7 months. Seven animals (ROc10 died on day 140 p.i. due to post-surgical [LN biopsy] complications) received 2 courses of IL-21 treatment (100 μg/kg s.c.) weekly for 6 weeks at the beginning (from days 67–105 p.i.) and at the end (from days 203–241 p.i.) of ART, as well as 4 additional administrations upon ART interruption (day 271 p.i.). The remaining 8 animals served as ART-treated controls. On day 270 p.i., ART was interrupted, and all the animals were monitored for 8 additional months. PB, RB, and LN biopsies were collected at the indicated time points. (B and C) Plasma SIVmac₂₃⁹ RNA levels expressed as copies/ml (LOD, 60 copies/ml, dashed line) are shown for each individual animal (B) and as an average (C) in IL-21–treated (orange circles) versus control (black squares) RMs. (D–G) CD4+ T cell levels, expressed as a fraction of live CD3+ T cells, were compared between IL-21-treated and control RMs in PB (D), RB (F), and LN (G). In PB, CD4+ T cells were also expressed as absolute counts (cells/μl blood; E). Gray shaded area represents the time of ART treatment, and the orange arrows mark IL-21 administrations. Averaged data are presented as the mean ± SEM. cART, combination ART.
The Journal of Clinical Investigation

RESEARCH ARTICLE

Figure 2. IL-21 supplementation improves mucosal immunity in ART-treated, SIV-infected RMs. (A and B) Representative staining for IL-17 (A) and IL-22 (B) within intestinal CD4+ T cells in IL-21-treated (top plots) and control (bottom plots) RMs before infection (day –20), after infection but before ART and IL-21 initiation (day 58 p.i.), and at 3 different experimental time points on ART (days 25, 75, and 200). (C and F) Longitudinal assessment of the frequency of intestinal CD4+ T cells producing IL-17 (C), IL-22 (D), IFN-γ (E), and IL-2 (F) in IL-21-treated (n = 7) and control (n = 8) RMs. (G and H) Rectal mucosa tissues were stained for MPO (brown) as a marker for PMNs. (G) Representative MPO staining (original magnification, ×200) in 1 IL-21-treated RM (top panels) and 1 control RM (bottom panels) before ART (day 58 p.i.) and at day 25 (day 85 p.i.) and day 200 (day 256 p.i.) on ART. (H) Random, high-powered (×400) images of gut LP were taken, and the percentage of area staining for MPO was determined in IL-21-treated and control RMs. Shaded area represents the time of ART treatment, and orange arrows represent IL-21 administrations. Averaged data were presented as the mean ± SEM. Repeated-measures analyses were performed with a means model (SAS PROC MIXED, version 9) to generate statistical outcomes. *P < 0.05; **P < 0.01; ***P < 0.001.

To assess the impact of IL-21 supplementation on this marker of mucosal immune dysfunction, we performed IHC to measure PMN infiltration in colorectal biopsy tissues from IL-21-treated and control animals before ART (day 58 p.i.) and at early (day 85 p.i.) and late (day 256 p.i.) experimental time points on ART (Figure 2G). In IL-21-treated RMs, but not in controls, the levels of MPO+ PMNs in the lamina propria (LP), in both early and late ART, were significantly lower than the levels observed on day 58 p.i. (P = 0.0078 and P = 0.0469, respectively; Figure 2H) and were thus consistent with a decrease of intestinal inflammation and, possibly, improved mucosal integrity following IL-21 treatment. Furthermore, during early ART, MPO+ PMN levels were significantly lower in IL-21–treated RMs as compared with levels in controls (P = 0.0207; Figure 2H), consistent with the higher numbers of Th17 and Th22 cells at the same experimental point. At the later time point (day 256 p.i.), ART alone became more effective at reducing MPO expression in PMNs, resulting in comparable MPO levels in the 2 groups (P = 0.6828; Figure 2H), which is consistent with the reduced differences in Th17 and Th22 cell levels at the same experimental time point.

Taken together, these data indicate that IL-21 administration improves the reconstitution of intestinal Th17 and Th22 cells and reduced intestinal inflammation in ART-treated, SIV-infected RMs.

IL-21 treatment reduces residual T cell activation and proliferation in ART-treated, SIV-infected RMs. Preferential loss of intestinal Th17 and Th22 cells is a key mechanism of mucosal immune dysfunction and chronic immune activation during pathogenic HIV/SIV infections (8, 13, 14, 23, 24). To investigate whether the higher IL-21–induced numbers of intestinal Th17 and Th22 cells were associated with reductions in T cell activation and/or proliferation when on ART, we next examined the frequencies of CD4+ and CD8+ T cells expressing the activation markers HLA-DR and CD38 and/or the proliferation marker Ki-67. We found that IL-21–treated RMs showed a more rapid — i.e., already evident at day 25 on ART (day 85 p.i.) — and more pronounced reduction of activated memory (CD28CD95+) CD4+ and CD8+ T cells in PB (Figure 3, A and D) and RB (Figure 3, G and J) up to day 200 on ART (day 256 p.i.), and a similar observation was made in the LN (Supplemental Figure 7, A and B). Furthermore, IL-21–treated RMs showed a more rapid and pronounced reduction in both memory CD4+ and CD8+ T cell proliferation levels in rectum (P ≤ 0.01; Supplemental Figure 8, A and B) and blood (P ≤ 0.01; data not shown). Interestingly, in blood (Figure 3, B and C), but not in RB (Figure 3, H and I), the reduction of immune activation was more pronounced for the key population of CM CD4+ T cells compared with that observed in EM CD4+ T cells. This was specific for CD4+ lymphocytes, since IL-21–treated RMs have lower levels of activation in both blood (Figure 3, E and F) and RB (Figure 3, K and L) CM and EM CD8+ T cells. Finally, plasma levels of soluble inflammatory markers such as IP-10, which are associated with HIV morbidity and mortality (days 143 and 200 on ART; P = 0.0401) and C-reactive protein (CRP) (day 75 on ART; P = 0.0323), were also significantly lower in IL-21–treated RMs as compared with levels in ART-only controls (Supplemental Figure 8, C and D).

These data indicate that IL-21 supplementation in ART-treated, SIV-infected RMs is associated with a more rapid and pronounced reduction of residual immune activation levels.

IL-21 treatment upregulates the expression of genes regulating antimicrobial immunity in ART-treated, SIV-infected RMs. We further explored the effect of IL-21 supplementation on ART-treated, SIV-infected RMs by comparing the whole transcriptome, as assessed by RNA sequencing (RNA-seq), in peripheral blood mononuclear cells (PBMCs) collected before ART (day 58 p.i.) and at 2 experimental time points on ART (days 50 and 200 on ART) in our 2 groups of animals. Changes in the expression of a large number of shared genes were observed in both IL-21–treated and control samples as a result of ART-induced viral suppression. Differential regulation between the 2 groups of RMs was observed in 53 genes at day 50 and in 42 genes at day 200 on ART (Q < 0.05) (Figure 4, A and E). Specifically, and consistent with the increased levels of Th17 and Th22 cell subsets (Figure 2), numerous genes associated with antimicrobial immunity were significantly upregulated in IL-21–treated animals as compared with controls at day 50 p.i. (Figure 4B). Among these, LTF, whose protein product is lactotransferrin, a major iron-binding protein with a broad range of antimicrobial and antiinflammatory functions (25), showed a 29-fold upregulation. Of note, lactotransferrin plays a key role in immunity against Candida albicans, an important opportunistic pathogen and cause of morbidity and mortality in HIV-infected subjects (26) and against which Th17 cells are highly specialized (27). LCN2 (lipocalin 2) and DEFA1 (defensin α1), both of which participate in neutrophil-mediated antimicrobial immunity, were...
IL-21 treatment reduces viral persistence in ART-treated, SIV-infected RMs. Recent studies have linked residual immune activation to HIV persistence (33–35). Thus, we sought to determine whether the IL-21–induced reduction of immune activation and inflammation impacted the level of virus persistence during ART by measuring plasma levels of SIV RNA using an ultrasensitive assay (LOD, 3 copies of SIV RNA/ml). As shown in Figure 5, we found that IL-21–treated RMs showed a progressive reduction in plasma SIV RNA levels compared with ART-only controls, with the fraction of RMs with an undetectable viral load remaining stable between days 75 and 200 on ART in controls (3 of 8 animals; 37.5%) but gradually increasing from 28.5% to 85.7% of animals in the IL-21–treated group over time (P = 0.03, test for interaction between time on study and treatment group; Figure 5A). This trend resulted in the levels of residual viremia being significantly lower in IL-21–treated RMs compared with controls by the end of the 200 days on ART (P = 0.0203). We next measured the frequency of cells harboring SIV DNA in the colorectum at 2 experimental time points on ART. Consistent with the data obtained for residual viremia, the reduction of SIV DNA levels (copies per 10^4 cell equivalents) in RB biopsies between days 50 and 200 on ART was more pronounced in IL-21–treated RMs (P = 0.0156) than in controls (P = 0.1484) (Figure 5B) and therefore resulted in lower levels of SIV DNA in treated animals than in controls at day 200 on ART (P = 0.0607). The possibility of a link between immune activation and SIV persistence is supported by the observation that the frequencies of intestinal CD8^+ HLA-DR^+CD38^+ T cells at day 50 (r = 0.6368; P = 0.0107) and day 200 (r = 0.6314; P = 0.0116) on ART positively correlated with SIV DNA content at day 200 on ART (Figure 5C).

In addition, the frequency of CD4^+ T cells expressing PD1, a subset of cells enriched in HIV reservoirs (35), was also significantly lower in RB biopsies of IL-21–treated RMs than in controls at day 200 on ART (Supplemental Figure 10A). Of note, plasma viremia at ART initiation correlated significantly with SIV DNA contents in blood CD4^+ T cells (r = 0.7821; P = 0.0009) and trended toward significance with SIV DNA copies in RB (r = 0.5071; P = 0.0562) at day 200 on ART, but did not correlate with the frequencies of intestinal CD8^+ HLA-DR^+CD38^+ T cells at day 50 or day 200 on ART (Supplemental Table 3).

Finally, we measured the levels of CD4^+ T cells harboring replication-competent virus using a modified quantitative viral outgrowth assay (QVOA) previously described for SIV-infected RMs (36, 37). Highly purified LN CD4^+ T cells were isolated from 4 IL-21–treated and 4 control RMs at the last experimental time point on ART (QVOA requires a large number of cells, thus we were limited to doing this assay only in animals with a large number of cryopreserved cells). Purified CD4^+ T cells were cocultured with the CEMx174 cell line, and frequencies of cells expressing p27 (see Figure 6A showing a representative staining), as well as levels of SIV RNA released in the supernatant, were quantified on days 9, 16, and 25 after coculture. Remarkably, all 4 IL-21–treated RMs showed levels of p27 expression and SIV RNA in supernatant that were significantly lower than those in controls at all tested experimental time points (Figure 6, B and C). As a result, the frequencies of latently infected cells, expressed as infectious units per million (IUPM) CD4^+ T cells, were significantly lower in IL-21–treated RMs than in controls (Figure 6D).

Figure 3. IL-21 supplementation limits residual T cell activation in ART-treated, SIV-infected RMs. (A–F) Longitudinal assessment of the activation levels of total memory (A and D), CM (B and E), and EM (C and F) CD4^+ (A–C) and CD8^+ (D–F) T cells in blood (PB). (G–L) Longitudinal assessment of the activation levels of total memory (G and J), CM (H and K), and EM (I and L) CD4^+ (G–I) and CD8^+ (J–L) T cells in colorectum (RB). T cell activation was assessed by dual expression of the immune activation markers HLA-DR and CD38. IL-21–treated animals (n = 7) are indicated by orange circles and controls (n = 8) by black squares. Shaded area represents the time of ART treatment, and orange arrows represent IL-21 administrations. Averaged data are presented as the mean ± SEM. Repeated-measures analyses were performed with a means model (SAS PROC MIXED, version 9) to generate statistical outcomes. *P < 0.05; **P < 0.01; ***P < 0.001; ‡P < 0.0001.
IL-21 supplementation limits both inflammation and viral persistence in SIV-infected RMs and support the possibility of a direct link between mucosal immunity, inflammation, and HIV persistence. Supporting this molecular link, SIV DNA content in purified blood CD4+ T cells at the latest time point on ART (day 256 p.i.) correlated (a) negatively with the levels of intestinal Th17 ($r = -0.7632; P = 0.0013$; Supplemental Figure 11A) and Th22 cells ($r = -0.6429; P = 0.0116$; Supplemental Figure 11C) before ART (day 58 p.i.); (b) negatively with the levels of intestinal Th17 cells on ART (day 105 p.i.; $r = -0.5898; P = 0.0223$; Supplemental Figure 11B); and (c) positively with the levels of intestinal CD4+Ki-67+ T cells on ART (day 84 p.i.; $r = 0.5893; P = 0.0232$; Supplemental Figure 11D). Moreover, at the latest time point on ART, the levels of activated (HLA-DR/CD38+) circulating CD4+ ($r = 0.6885; P = 0.0062$; Supplemental Figure 11E) and CD8+ ($r = 0.5494; P = 0.0339$; Supplemental Figure 11F) T cells positively correlated with residual plasma viremia. Finally, plasma levels of IP-10 (day 203 p.i.; $r = 0.7575; P = 0.0011$; Supplemental Figure 11G) and CRP (day 135 p.i.; $r = 0.6986; P = 0.0050$; Supplemental Figure 11H) on ART positively correlated with SIV DNA content in intestinal tissues and residual plasma viremia, respectively. Of note, plasma viremia before ART (day 58 p.i.) negatively correlated with pre-ART levels of intestinal Th17 ($r = -0.6988; P = 0.0047$) and Th22 ($r = -0.4500; P = 0.0944$) cells, but did not correlate with markers of immune activation on ART (Supplemental Table 3).

**IL-21-treated RMs show better control of virus replication and immune activation after ART interruption.** The design of the current study included a structured interruption of ART after 7 months as a tool to determine whether the reduced inflammation and virus persistence observed during ART in IL-21-treated RMs (Figures 3 and 5) would translate into superior control of viral replication and immune activation following ART interruption. In this part of the study, all SIV-infected RMs were monitored for 8 months after interruption of ART (off ART) and then euthanized (Figure 1). During the off-ART follow-up period, plasma viral loads were, on average, 0.7 logs lower in IL-21-treated RMs when compared with those in ART-only controls, although, due to animal-to-animal variability in this relatively limited cohort, the difference between the 2 groups did not reach statistical significance at any of the experimental time points (Figure 7A). The difference was particularly pronounced starting at day 60 off ART, after which viral loads consistently increased (up to 1 log) in controls but remained stable in IL-21-treated animals (Figure 7A). To further investigate potential differences in the viral rebound after ART interruption, we then compared the levels of plasma viremia at different experimental time points off ART with the pre-ART levels. We found that plasma viremia was significantly reduced as compared with pre-ART levels up to day 60 off ART in both groups (data not shown); however, starting at day 90 off ART, plasma viremia rebounded to levels similar to those observed before ART in control RMs, while IL-21-treated animals maintained plasma SIV RNA copies that were significantly lower than the pre-ART baseline up to day 240 off ART (Figure 7B). As expected, plasma viremia levels before ART (day 58 p.i.) strongly correlated with those after ART interruption (shown for days 90 and 240 off ART in Supplemental Figure 12), thus highlighting the critical importance of matching experimental groups for viremia before ART initiation when testing interventions, as in our study. We next measured the levels of SIV DNA in purified blood CD4+ T cells after ART interruption (Figure 7C) and found that, in the majority of control RMs, these levels increased as compared with their on-ART levels ($P = 0.0031$; day 180 off ART), and, in fact, they were no longer different from pre-ART levels ($P = 0.0829$). In contrast, in IL-21-treated RMs, the levels of SIV DNA in blood CD4+ T cells did not increase following ART interruption ($P = 0.1931$ vs. on-ART levels) and remained significantly lower ($P = 0.0407$) compared with pre-ART levels (Figure 7C). Interestingly, in 2 control animals, the levels of CD4+ T cell SIV DNA content decreased after ART interruption. Both animals were Mamu-A*01 and had among the lowest set-point viral loads before ART initiation, thus suggesting the possibility of a genetically predisposed control of viral replication (38). Of note, when considering only Mamu-A*01 animals, we found that the levels of SIV DNA content off ART rebounded to levels significantly higher than on-ART levels in all 4 controls, but only in 1 of the 4 IL-21-treated animals (Figure 7D). As a result, CD4+ T cell–associated SIV DNA content on day 180 after ART interruption was significantly lower in IL-21-treated animals compared with control RMs (mean ± SEM log_{10}: 3.11 ± 0.52 vs. 4.55 ± 0.11; $P = 0.01$; Figure 7D).

We next measured, in the same SIV-infected RMs, the levels of activated or proliferating T cells after ART interruption. We found that IL-21-treated animals maintained CD4+HLA-DR/CD38+ and CD8+HLA-DR/CD38+ T cells at necropsy was significantly lower in the LNs of IL-21-treated RMs compared with that detected in control RMs ($P = 0.0260$; Supplemental Figure 13A), with a similar trend found for CD8+HLA-DR/CD38+ T cells (Supplemental Figure 13B). Finally, the improved control of chronic immune activation and viral replication resulted in a higher CD4+/CD8+ ratio after ART interruption in IL-21-treated RMs, with values that become statistically significant at day 180 off ART compared with control RMs (Supplemental Figure 13C). Taken together, these data suggest that IL-21 supplementation of ART results in beneficial effects upon ART discontinuation, in particular in reducing chronic immune activation.
The Journal of Clinical Investigation

ResearCh aR ticle

The Journal of Clinical Investigation  ResearCh aR ticle

The rationale for using IL-21 was 4-fold. First, this cytokine regulates processes that are compromised during pathogenic HIV/SIV infections, including differentiation of Th17 cells (5–7), maintenance of functional CD8+ T cells (39–42), and differentiation of memory B cells and Ab-secreting plasma cells (43–46). Second, SIV infection is associated with a loss of IL-21-producing cells in the gut, which is correlated with the severity of intestinal Th17 cell depletion (15). Third, administration of IL-21 during acute SIV infection of RMs is beneficial for the reconstitution of these cells, leading to a reduction in residual viremia and enhanced immune function.

SIV-infected RMs and determined how this intervention impacted immune reconstitution, residual immune activation, and viral persistence during ART as well as after ART interruption. The rationale for using IL-21 was 4-fold. First, this cytokine regulates processes that are compromised during pathogenic HIV/SIV infections, including differentiation of Th17 cells (5–7), maintenance of functional CD8+ T cells (39–42), and differentiation of memory B cells and Ab-secreting plasma cells (43–46). Second, SIV infection is associated with a loss of IL-21-producing cells in the gut, which is correlated with the severity of intestinal Th17 cell depletion (15). Third, administration of IL-21 during acute SIV infection of RMs is beneficial for the reconstitution of these cells, leading to a reduction in residual viremia and enhanced immune function.

Discussion

While ART has a major beneficial impact on HIV disease progression, this treatment is associated with residual morbidity related to a number of persistent immune abnormalities and to the presence of a reservoir of latently infected cells that will cause a rebound of virus replication if ART is interrupted. As such, numerous concepts and products are aggressively being explored as novel interventions to be added to standard ART in order to reduce or possibly eliminate these immunological and/or virological aspects of residual HIV disease on ART. In the current study, we administered IL-21, a potent immunomodulatory cytokine, to ART-treated, SIV-infected RMs and determined how this intervention impacted immune reconstitution, residual immune activation, and viral persistence during ART as well as after ART interruption. The rationale for using IL-21 was 4-fold. First, this cytokine regulates processes that are compromised during pathogenic HIV/SIV infections, including differentiation of Th17 cells (5–7), maintenance of functional CD8+ T cells (39–42), and differentiation of memory B cells and Ab-secreting plasma cells (43–46). Second, SIV infection is associated with a loss of IL-21-producing cells in the gut, which is correlated with the severity of intestinal Th17 cell depletion (15). Third, administration of IL-21 during acute SIV infection of RMs is beneficial for the reconstitution of these cells, leading to a reduction in residual viremia and enhanced immune function.

Figure 5. IL-21 supplementation reduces residual plasma viremia and SIV DNA content in ART-treated, SIV-infected RMs. (A) Residual levels (copies/ml) of plasma SIVmac239 RNA were assessed by ultrasensitive viral load assay (LOD, 3 copies per ml; dashed lines) at 3 experimental time points on ART: day 75 (day 135 p.i.), day 104 (day 164 p.i.), and day 200 (day 256 p.i.). Percentages at the top of the graphs indicate the fraction of RMs with undetectable viremia at the different time points. When all 3 time points were considered, the decrease in residual viremia was significantly higher in IL-21-treated (n = 7) (orange circles) RMs compared with viremia levels in controls (n = 8) (black squares) (P = 0.03). When a single experimental time point was considered, SIVmac239 RNA copies were significantly lower in IL-21-treated RMs at day 200 on ART (P = 0.0203). (B) Copies of total SIVmac239 DNA per 10^6 intestinal cell equivalents were longitudinally quantified at days 50 and 200 on ART. SIVmac239 DNA content significantly decreased between the 2 experimental points only in IL-21-treated animals (P = 0.0156). (C) Correlations between the levels of activated (HLA-DR+CD38+) CD8+ T cells at days 50 and 200 on ART and the content of SIV DNA in the rectum at day 200 on ART (top panels). Correlations between plasma viremia before ART initiation and the content of SIV DNA in PBMCs and in the rectum at day 200 on ART (bottom panels). Averaged data are presented as the geometric mean. Repeated-measures and GEE analyses were used (SAS PROC MIXED and GENMOD, version 9) to generate statistical outcomes. VL, viral load.
in all SIVmac-infected RMs, highlighting the relevance of the ART-treated, SIV-infected RM model to test immune-based interventions targeting residual immune activation and virus persistence in HIV-infected humans on suppressive ART.

IL-21 administration was safe in the context of ART-treated, SIV-infected RMs. When compared with ART-only controls, RMs receiving ART plus IL-21 showed (a) better reconstitution of intestinal Th17 and Th22 cells and a selective enrichment in genes that participate in Th17 and Th22 cell–orchestrated antimicrobial immunity, and (b) a significantly more rapid and pronounced reduction of the levels of cellular immune activation in rectum and blood, as well as of plasma levels of the inflammatory markers associated with preserved intestinal Th17 cells and limited microbial translocation (16). Last, IL-21 is currently being evaluated in several phase I and II cancer clinical trials, with limited toxicity and encouraging single-agent activity (17, 47–49). Importantly, a historic limitation of the SIV/RM model for studies of HIV residual disease, i.e., the lack of an optimized ART that fully suppresses virus replication, has been recently overcome, with a number of studies showing that the combination of tenofovir, emtricitabine, an integrase inhibitor (raltegravir or dolutegravir), and darunavir can durably suppress SIV infection of RMs to clinically relevant levels (50–53). Indeed, in the current study, we achieved prolonged suppression of plasma viral replication (<60 SIV RNA copies/ml) in all SIVmac-infected RMs, highlighting the relevance of the ART-treated, SIV-infected RM model to test immune-based interventions targeting residual immune activation and virus persistence in HIV-infected humans on suppressive ART.

IL-21 administration was safe in the context of ART-treated, SIV infected RMs. When compared with ART-only controls, RMs receiving ART plus IL-21 showed (a) better reconstitution of intestinal Th17 and Th22 cells and a selective enrichment in genes that participate in Th17 and Th22 cell–orchestrated antimicrobial immunity, and (b) a significantly more rapid and pronounced reduction of the levels of cellular immune activation in rectum and blood, as well as of plasma levels of the inflammatory markers associated with preserved intestinal Th17 cells and limited microbial translocation (16). Last, IL-21 is currently being evaluated in several phase I and II cancer clinical trials, with limited toxicity and encouraging single-agent activity (17, 47–49). Importantly, a historic limitation of the SIV/RM model for studies of HIV residual disease, i.e., the lack of an optimized ART that fully suppresses virus replication, has been recently overcome, with a number of studies showing that the combination of tenofovir, emtricitabine, an integrase inhibitor (raltegravir or dolutegravir), and darunavir can durably suppress SIV infection of RMs to clinically relevant levels (50–53). Indeed, in the current study, we achieved prolonged suppression of plasma viral replication (<60 SIV RNA copies/ml) in all SIVmac-infected RMs, highlighting the relevance of the ART-treated, SIV-infected RM model to test immune-based interventions targeting residual immune activation and virus persistence in HIV-infected humans on suppressive ART.

IL-21 administration was safe in the context of ART-treated, SIV infected RMs. When compared with ART-only controls, RMs receiving ART plus IL-21 showed (a) better reconstitution of intestinal Th17 and Th22 cells and a selective enrichment in genes that participate in Th17 and Th22 cell–orchestrated antimicrobial immunity, and (b) a significantly more rapid and pronounced reduction of the levels of cellular immune activation in rectum and blood, as well as of plasma levels of the inflammatory markers associated with preserved intestinal Th17 cells and limited microbial translocation (16). Last, IL-21 is currently being evaluated in several phase I and II cancer clinical trials, with limited toxicity and encouraging single-agent activity (17, 47–49). Importantly, a historic limitation of the SIV/RM model for studies of HIV residual disease, i.e., the lack of an optimized ART that fully suppresses virus replication, has been recently overcome, with a number of studies showing that the combination of tenofovir, emtricitabine, an integrase inhibitor (raltegravir or dolutegravir), and darunavir can durably suppress SIV infection of RMs to clinically relevant levels (50–53). Indeed, in the current study, we achieved prolonged suppression of plasma viral replication (<60 SIV RNA copies/ml) in all SIVmac-infected RMs, highlighting the relevance of the ART-treated, SIV-infected RM model to test immune-based interventions targeting residual immune activation and virus persistence in HIV-infected humans on suppressive ART.

IL-21 administration was safe in the context of ART-treated, SIV infected RMs. When compared with ART-only controls, RMs receiving ART plus IL-21 showed (a) better reconstitution of intestinal Th17 and Th22 cells and a selective enrichment in genes that participate in Th17 and Th22 cell–orchestrated antimicrobial immunity, and (b) a significantly more rapid and pronounced reduction of the levels of cellular immune activation in rectum and blood, as well as of plasma levels of the inflammatory markers associated with preserved intestinal Th17 cells and limited microbial translocation (16). Last, IL-21 is currently being evaluated in several phase I and II cancer clinical trials, with limited toxicity and encouraging single-agent activity (17, 47–49). Importantly, a historic limitation of the SIV/RM model for studies of HIV residual disease, i.e., the lack of an optimized ART that fully suppresses virus replication, has been recently overcome, with a number of studies showing that the combination of tenofovir, emtricitabine, an integrase inhibitor (raltegravir or dolutegravir), and darunavir can durably suppress SIV infection of RMs to clinically relevant levels (50–53). Indeed, in the current study, we achieved prolonged suppression of plasma viral replication (<60 SIV RNA copies/ml) in all SIVmac-infected RMs, highlighting the relevance of the ART-treated, SIV-infected RM model to test immune-based interventions targeting residual immune activation and virus persistence in HIV-infected humans on suppressive ART.
IP-10 and CRP (at selected time points). Remarkably, IL-21 treat-
ment was associated with reduced plasma viremia, lower levels
of SIV DNA in the rectum, and lower levels of replication-competent
virus in LN-derived CD4+ T cells during ART. Furthermore, IL-21-
treated RMs showed lower levels of immune activation and better
control of virus replication up to 8 months (the latest tested exper-
imental points) after ART interruption.

The current data in a relevant NHP model provide, for the first
time to our knowledge, direct in vivo evidence of the ability of IL-21
to reduce residual immune activation during long-term ART. This
is a potentially important result, since residual immune activation
is considered a key contributor to non–AIDS-related morbidity and
mortality in ART-treated, HIV-infected individuals (1, 3). More
generally, this study represents, to our knowledge, the first test-of-
concept in a relevant preclinical animal model of the hypothesis
that an immune-based intervention that reduces residual immune
activation under ART can also limit virus persistence. Using sen-
sitive assays, we found that the levels of SIV RNA in plasma, cell-
associated SIV DNA in the rectum, and replication-competent virus
in LN-derived CD4+ T cells were markedly reduced at day 200 on
ART in RMs also receiving IL-21. To the best of our knowledge, these
are the first in vivo data directly supporting a causal link between
residual immune activation and virus persistence during ART. While,
on the basis of our data, we propose increased mucosal integrity as
a key contributor to the reduced residual immune activation during
ART in IL-21-treated RMs, the mechanisms by which a reduction
of immune activation can limit virus persistence under ART may
be very complex and may include (a) a reduction in the number of
activated CD4+ T cells that serve as targets for the infection and
that may become a persistent reservoir, and (b) a better mainte-
nance and/or restoration of HIV/SIV-specific immune responses,
thus resulting in a better clearance of productively infected cells
and/or latently infected cells in which virus infection has been
reactivated. Although this study was not aimed at determining the
mechanism(s) of the link between residual immune activation and
virus persistence, further studies that include elective necropsy of
the SIV-infected RMs during ART may be able to provide critical
insights on this important question. Moreover, the activity of IL-21
in increasing mucosal integrity was more pronounced when IL-21
was administered earlier during ART as compared with admin-
istration late in ART. Thus, further studies are needed to confirm
the benefit of IL-21 administration on mucosal integrity in already
fully suppressed SIV-infected animals. As for all therapeutic inter-
ventions improving reconstitution of CD4+ T cells during ART, one
potential concern is that, by increasing Th17 cell levels, we also
expand the viral reservoir harbored by these cells. In this regard, it
is important to note that Th17 cell levels are never greater than those
detected before SIV infection; thus, IL-21 treatment does not induce
a nonphysiological accumulation of Th17 cells.

An additional and perhaps surprising result of this study is
that the beneficial effects of IL-21 supplementation seem to
include better control of immune activation and, although to a
lower extent, viral replication following ART interruption. This
observation is intriguing in that it supports the idea that immune-
based interventions during ART-induced suppression of virus
replication may have an impact on the dynamics of the host-virus
interaction that persists even after ART discontinuation, when
virus replication has rebounded to levels similar to those observed
before ART initiation. The observation that IL-21 supplementa-
tion might have caused a significant and persistent reduction in
immune activation despite robust virus replication is reminiscent
of the phenotype typical of the nonpathogenic SIV infection of
natural hosts such as the sooty mangabeys (54). Of note, in both
IL-21-treated and control RMs, plasma viremia at ART initiation
directly correlated with the extent of viral rebound after ART
interruption, thus highlighting the critical importance of match-
ing experimental groups before ART initiation in studies aimed at
testing the curative potential of therapeutic interventions. Future
studies in which the ART plus IL-21–treated, SIV-infected RMs
are followed up for longer periods after ART interruption will be
needed to determine the impact of this treatment on the clinical
progression of SIV infection.

In summary, we tested a novel immune-based intervention in
an in vivo NHP model highly relevant for studies of HIV residual
immune dysfunction and virus persistence under ART. By using
the well-established model of SIV infection in RMs in the context
of ART-mediated suppression of virus replication, we determined
that IL-21 supplementation is associated with key benefits in terms
of reducing both the residual immune activation and inflammation
and the level of virus persistence in ART-treated, SIV-infected RMs.
In addition, these in vivo data support the hypothesis of a mechanis-
tic link between residual immune activation and virus persistence
that may have important implications in the pathogenesis of resid-
ual HIV disease under ART. Taken together, these results provide a
rationale for further exploration of IL-21 as an immune-based inter-
vention in preclinical and clinical studies of HIV/SIV eradication.

Methods

Animals, SIV infection, and ART regimen. Sixteen RMs, all housed at
the YNPRC in Atlanta, Georgia, were included in the study. All ani-

Figure 7. Effects of IL-21 treatment on immune activation and viral repli-
cation following ART interruption. (A) Longitudinal assessment of plasma
SIVmac239 RNA copies (presented as the mean ± SEM) up to 8 months
after ART interruption. Starting from day 90 off ART, viremia levels were
lower (average of a 0.7-log reduction) in IL-21-treated RMs up to day 240
off ART. (B) Plasma viral loads before ART (day 58 p.i.) were compared with
those at days 140, 180, and 240 off ART in IL-21–treated (n = 7) and control
(n = 8) RMs. At all 3 experimental time points off ART (as well as at day 90
off ART, not shown), viral loads remained significantly lower than before
ART in IL-21-treated RMs but not in controls. (C) Cell-associated SIV DNA
content (total) in purified blood CD4+ T cells was longitudinally determined
before ART initiation (day 58 p.i.), during ART (days 50 and 200 on ART),
and after ART interruption (days 90 and 180 off ART) in IL-21–treated and
control RMs. At day 180 off ART, SIVmac239 DNA levels were significantly
higher than levels during ART in control animals, but not in IL-21–supple-
mented animals. (D) Differences were even more pronounced when only
Mamu-A*01+ animals were analyzed. (E) Percentages of memory CD4+
(left panels) and CD8+ (right panels) T cells coexpressing the activation
markers HLA-DR and CD38 were longitudinally determined at different
experimental time points off ART in PB (top panels) and RB (bottom
panels) biopsies. T cell activation levels were significantly lower in IL-21–
treated RMs compared with levels in control RMs. IL-21–treated animals
are indicated with orange circles and controls with black squares. Averaged
data are presented as the mean ± SEM. Repeated-measures analyses were
performed with a means model (SAS PROC MIXED, version 9) to generate
statistical outcomes.
mals were *Mamu*-B’08 and -B’17, while 8 of them were *Mamu*-A’01 (RLm12, R1b12, Rp11, RChb12, RVt10, RKg11, ROC10, and RP8). The 16 RMs were randomized into 2 groups (group 1: IL-21 plus ART treatment; group 2: ART-only controls) of 8 animals on the basis of age (group 1: 6.9 ± 0.63 years; group 2: 6.7 ± 0.86 years), weight (7.4 kg ± 0.6 kg vs. 6.7 kg ± 0.3 kg), and *Mamu*-A’01 status (4 in each group). All 16 animals were infected i.v. with 300 TCID_{50} SIVmac259 (day 0). Starting on day 60 p.i., all animals were treated with a 5-drug ART regimen consisting of 2 reverse transcriptase (RT) inhibitors (PMPA, 20 mg/kg and FTC, 30 mg/kg), 1 integrase inhibitor (raltegravir, 100 mg/bid), and 1 protease inhibitor (darunavir, 375 mg/bid with ritonavir, 50 mg/bid, as a boosting supplementation) for 7 months. In addition, the 8 animals in group 1 received 2 cycles of treatment with recombinant IL-21-IgFc (rIL-21-IgFc) (16) (100 μg/kg s.c., once per week for 6 weeks) at the beginning (from days 67 to 105 p.i.) and at the end (from days 203 to 241 p.i.) of ART, as well as 4 additional administrations upon ART interruption (day 271 p.i. or day 1 after ART discontinuation). The remaining 8 animals in group 2 served as ART-treated controls (Figure 1A). We did not notice any side effects or increased complications in the SIV-infected RMs that had been treated with IL-21 compared with those treated with ART alone. ROC10, in the IL-21-treated group, was euthanized on day 140 p.i. due to postsurgical (LN biopsy) complications. Markers in this animal were comparable to those of the others treated with IL-21, including greater Th17 and Th22 cell levels compared with those in ART-treated controls (Supplemental Table 4). On day 270 p.i., ART was interrupted, and all animals were monitored for an additional 8 months. PB, RB, and LN biopsies were collected at numerous experimental time points throughout the study (Figure 1).—induced protein 10 (IP-10) and CRP levels were measured in plasma using commercially available ELISA kits according to the manufacturer’s instructions. IP-10 levels were quantified using a human IP-10 Quantikine ELISA kit (R&D Systems) and expressed as pg/ml. Plasma CRP levels were measured using a mouse CRP ELISA kit (Life Diagnostics Inc.) and expressed as μg/ml.

**Cell-associated SIV DNA within blood CD4^+ T cells.** Quantitative assessment of cell-associated total SIV DNA within circulating CD4^+ T cells at day 58 p.i., at days 50 and 200 on ART, and at days 90 and 180 off ART was performed using a modified version of a recently published quantitative nested PCR assay for cell-associated total HIV DNA (59). In a first round of PCR, total SIV DNA was amplified with 2 primers that anneal within a conserved region of the long terminal repeat
The forward primer SIV-LF1 was extended with a lambda phage–specific heel sequence at the 5’ end of the oligonucleotide. Primers targeting the CD3 gene (HCD3OUT-5’ and HCD3OUT-3’) were also added to quantify the exact number of cells in the initial samples. Gag-LTR sequences were amplified from 15 μl lysate in a 50-μl reaction mixture composed of 1X Taq Buffer, MgCl₂, dNTP, SIV-LF1, SIV-R1, and Taq polymerase. The first-round PCR cycle conditions were as follows: a denaturation step of 8 minutes at 95°C and then 16 cycles of amplification (95°C for 1 minute, 62°C for 40 seconds, 72°C for 1 minute), followed by an elongation step at 72°C for 15 minutes. In a second round of PCR, the lambda T–specific primer (Lambda T) and the LTR primer (SIV-R2) were used to amplify SIV sequences obtained from the first amplification. Primers targeting CD3 were also used in another second-round PCR. Nested PCR was performed on one-tenth of the first-round PCR product in a mixture consisting of 1X Rotor-Gene Master Mix (QIAGEN), Lambda T primer, SIV-R2 primers, and SIV probe (Integrated DNA Technologies). For CD3 amplification, nested PCR was performed in a mixture composed of 1X Rotor-Gene Master Mix, HCD3IN 5’ and MamuCD3IN 3’ and MamuCD3 probe. Cycling was performed on the Rotor-Gene (QIAGEN) with a denaturation step (95°C for 4 minutes), followed by 40 cycles of amplification (95°C for 3 seconds, 60°C for 10 seconds). The total SIV DNA copy number was calculated using a standard curve as a reference. This standard curve consisted of serial dilution of the 3D8 cell lysates (carrying 1 integrated copy of SIV genome per cell) (60).

Quantification of replication-competent virus in purified CD4+ T cells during ART. LN cryopreserved, highly purified CD4+ T cells were cocultured at a 1:1 ratio with the CEMx174 cell line (NIH AIDS Research and Reference Reagent Program) in serial dilutions ranging from 1 × 10⁶ to 0.1 × 10⁶ cells per well. The cells were cultured in complete RPMI 1640 with 4 mM L-glutamine supplemented with 10% heat-inactivated FBS (Gemini Bio Products), penicillin (50 U/ml), streptomycin (50 μg/ml), and IL-2 (100 U/ml). Cultured cells were split, fed with fresh medium, and harvested and analyzed on days 9, 16 and 25. Flow cytometric analyses of intracellular SIV-Gag p27 expression (61) and SIV-Gag viral RNA (vRNA) (copies/ml) in the supernatant were used to determine positive wells. Replication-competent SIV levels in CD4+ T cells were compared between cell cultures from controls and IL-21-treated animals. The frequencies of infected cells were determined by the maximum likelihood method (62) and expressed in terms of IUPM CD4+ T cells.

RNA-seq analysis. RNA-seq analysis was conducted at the Yerkes Nonhuman Primate Genomics Core laboratory (http://www.yerkes.emory.edu/whp_genomics_core/). PBMCs at various time points were stored in QIAEN RLT buffer at -80°C. Total RNA was prepared using QIAEN RNaseasy kits. Polyadenylated transcripts were purified on oligo-dT magnetic beads, fragmented, reverse transcribed using random hexamers, and incorporated into barcoded cDNA libraries based on the Illumina TruSeq platform. Libraries were validated by microelectrophoresis and quantified, pooled, and clustered on Illumina TruSeq v3 flow cells. Clustered flow cells were sequenced on an Illumina HiSeq 1000 in 100-base single-read reactions. RNA-seq data were analyzed by alignment and annotation to the MacaM assembly of the Indian rhesus macaque genome (63) (available at http://www.unmc.edu/rhesusgenechip/index.htm#NewRhesusGenome).

Alignment was performed using STAR version 2.3.0e (64); parameters were set using the annotation as a splice junction reference, and unannotated, noncanonical splice junction mappings and nonunique mappings were removed from downstream analysis. Transcripts were annotated using MacaM assembly and annotation, version 7.6 (see previous URL address). RNA-seq reads and the normalized expression table were deposited in the NCBI’s Gene Expression Omnibus (GEO) database (GEO GSE73232). Transcript assembly, abundance estimates, and differential expression analysis were performed using Cufflinks, version 2.1.1, and Cuffdiff (65). RNA-seq data are expressed as fragments per kilobase mapped (FPKM), which is the default output by Cufflinks/Cuffdiff, in which reads and fragments mapping to an individual gene are normalized by the total number of kilobases that map to the reference genome for an individual sample; this calculation minimizes bias due to differences in sequencing depth between samples. Heatmaps and other visualizations were generated using the Partek Genomics Suite, version 6.6.

GSEA. GSEA was performed using the desktop module available from the Broad Institute (www.broadinstitute.org/gsea/). While conventional statistics for differential gene expression determine significance on the basis of variance on a single gene, GSEA uses a cumulative statistic based on multiple genes within a biological pathway, and these multiple genes are grouped together on the basis of their common function/characteristic or empirical data (66). Gene rank was calculated for the normalized expression table using the signal-to-noise metric. The ranked dataset was screened against the Broad Institute’s Molecular Signatures Database (http://www.broadinstitute.org/gsea/msigdb/index.jsp), curated (C2) and immunologic signatures (C7) gene sets, as well as against the ISG gene set, an immune activation dataset determined using previous data from our laboratory (67). We also generated unbiased sets of genes representing IL-21–regulated genes for GSEA testing. Gene sets with P values below 0.25 were considered significant according to the guidelines published on the GSEA home page.

IHC and quantitative image analysis. IHC and quantitative image analysis for the percentage of LP area that stained for MPO+ neutrophils was performed as previously described (68, 69).

Statistics. Repeated-measures analyses for each outcome (CD4+ T cells, CD4+Ki-67+ T cells, Th17 cells; plasma viral load, SIV DNA within blood CD4+ T cells, etc.) were performed with a means model using SAS PROC MIXED, version 9 (SAS Institute) providing separate estimates of the means by weeks after infection and treatment groups. A compound-symmetry variance-covariance form in repeated measurements was assumed for each outcome, and robust estimates of the standard errors of parameters were used to perform statistical tests and construct 95% CIs (70). The mean estimates and their 95% CIs were back transformed to the original scale and reported as the geometric mean with 95% CIs. The model-based means were unbiased with unbalanced and missing data, so long as the missing data are noninformative (missing at random). t tests were used to compare the differences between the model-based treatment means (least-squares means) at each time point and to compare mean differences over time within each treatment group. Specific statistical tests were generally performed within the framework of the mixed-effects linear model. However, selected statistical tests were performed for specific data subsets. All statistical tests were 2 sided and unadjusted for multiple comparisons. A P value below 0.05 indicated statistical significance. Because of the small sample sizes, results from these studies focus on the magnitude of the differences for each outcome, consistency of the findings, and biological significance. The generalized estimat-
Background and study aim: The role of microbial translocation in HIV infection and the potential of IL-21 as a therapeutic target for HIV-1 infection is reviewed.

Materials and methods: SIV-infected rhesus macaques treated with intravenous IL-21-IgFc for 56 weeks were compared with control animals treated with vehicle. Clinical parameters, peripheral blood mononuclear cell subsets and chemokine levels were measured. SIV viral load and virus-specific CD8 T cells were measured by viral load, plasma cell enumeration in blood, bone marrow, and secondary lymphoid organs, and intracellular cytokine analysis.

Results: IL-21 improved host survival. IL-21-IgFc therapy suppressed SIV plasma viremia and increased virus-specific CD8 T cells with enhanced functionality. The enhanced functionality included increased perforin and granzyme expression, increased virus-specific CD8 T cell proliferation, increased cytokine secretion, and increased cytokine mRNA expression.

Conclusions: IL-21-IgFc therapy provides protection from SIV infection with increased virus-specific CD8 T cell function, increased IL-17 and IL-22-producing T cells, and increased virus-specific plasma cells. IL-21-IgFc therapy could be used to treat microbially exposed HIV-infected patients.
The Journal of Clinical Investigation

Research Article


